ClinicalTrials.gg
CompletedNCT05583552IMpressUpdated Oct 2, 2026Results posted

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

A Phase 2 interventional study of Imetelstat sodium in Myelodysplastic Syndromes and Acute Myeloid Leukemia, sponsored by GCP-Service International West GmbH. Completed at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by GCP-Service International West GmbH · Phase 2, Interventional, and Treatment

Updated Oct 2, 2026Now CompletedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Myelodysplastic Syndromes with a site in France — 36 open to participants now, 54 under way, 13 of them phase 3. Myelodysplastic Syndromes · France.

Enrollment
118th of 172
46 · median 93
Started
2023
with 9 others
Phase 2
53 of 198
7 open now
Registered
170th of 198
by date

Among the 198 studies in Myelodysplastic Syndromes with a site in France, this one is the 118th largest by enrollment of the 172 interventional ones that give a count, is one of 10 that started in 2023, is one of 53 in phase 2, and was the 170th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

36 of the 198 studies in Myelodysplastic Syndromes with a site in France are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Myelodysplastic Syndromes with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.

03

Conditions studied

  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • Male and female ≥ 18 years at the first screening
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Initial diagnosis of AML or MDS according to WHO (World Health Organization) 2016 classification
  • At least one cytopenia
  • Failure to achieve complete or partial response or hematological improvement observed after at least six azacitidine monotherapy or four decitabine monotherapy based 4-week treatment cycles administered during the past two years OR Failure to achieve complete or partial response or hematological improvement observed after at least two 4-week treatment cycles with azacitidine plus venetoclax or with decitabine plus venetoclax during the past two years OR Relapse after initial complete or partial response or hematological improvement observed after at least six (azacitidine) or four (decitabine) based 4-week treatment cycles administered during the past two years OR Relapse after initial complete or partial response or hematological improvement observed after at least two 4-week treatment cycles with azacitidine plus venetoclax or with decitabine plus venetoclax during the past two years OR Intolerance to treatment with HMA-based therapy during the past two years
  • Not eligible for stem cell transplantation
  • ≥ 5% bone marrow blasts at screening
  • Off all other treatments for AML/MDS for at least 14 days; granulocyte colony-stimulating factor (G-CSF) and erythropoietin are allowed before and during the study as clinically indicated
  • (ECOG) performance status of 0-2
  • Biochemical laboratory test values must be within the defined limits.
  • Availability of blood counts and transfusion events for previous 16 weeks
  • Women of and practicing a highly effective method of consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies. For females, these restrictions apply for 3 months after the end of dosing.
  • A woman of childbearing potential must have a negative serum or urine pregnancy test at screening and agree to be tested on day 1 of every cycle and at End of Treatment (EOT)
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control. For males, these restrictions apply for 3 months after the end of dosing
  • Patients who are to, or not eligible for, therapy with approved and available FLT3 (FMS-like tyrosine kinase 3) or IDH1/IDH2 (Isocitrate dehydrogenase) inhibitors or other approved targeted therapies.

Exclusion criteria

Exclusion Criteria:

  • Chemotherapy within the 14 days prior to the first dose of imetelstat being administered (other than hydroxyurea)
  • Participant has known allergies, , or intolerance to imetelstat or its (refer to the Investigators Brochure (IB))
  • Participant has received an experimental or drug or used an invasive investigational medical device within 30 days prior to day 1 of Cycle 1
  • Prior treatment with imetelstat
  • Prior history of intensive chemotherapy or hematopoietic stem cell transplant
  • Major surgery within 4 weeks prior to day 1 of Cycle 1 (excluding the placement of vascular access and other minor surgical procedures)
  • Diagnosed or treated for other than MDS or AML, except:

Malignancy treated with curative intent and with no known active disease present for 3 years before day 1 of Cycle 1 Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease Adequately treated cervical carcinoma in situ without evidence of disease

  • cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of day 1 of Cycle 1, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the Functional Classification
  • Known history of (HIV) or any uncontrolled active systemic infection requiring IV antibiotics
  • Active systemic hepatitis infection requiring treatment (carriers of hepatitis virus are permitted to enter the study), or known acute or chronic liver disease including cirrhosis
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the participant 's safety, interfere with the imetelstat metabolism, or put the study outcomes at undue risk; Participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
  • Females who are pregnant or are currently breastfeeding or planning to become pregnant while enrolled in this study or within 3 months after the end of dosing
  • Participant is a man who plans to father a child while enrolled in this study or within 3 months after the end of dosing
  • Other:

Participant is in custody by order of an authority or a court of law Participation in another interventional clinical study within the last 3 months prior to signing the form (ICF) or simultaneous participation in other interventional clinical studies Previous assignment to treatment during this study Close affiliation with the investigator (e.g., a close relative) or persons working at the study site Participant is an employee of the sponsor or involved Contract Research Organization (CRO) Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the Participant's safety

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Single-arm imetelstat

    Drug: Imetelstat sodium

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Hematological Response Rate of Participants After Treatment With Imetelstat

    The combined response assessment criteria for MDS and AML based on IWG (International Working Group) 2018 criteria (MDS) and the criteria of the European LeukemiaNet (AML) will be used to define responders. The response rate is calculated as number of responders divided by the number of all participants of the analysis set.

    Time frame: Up to Week 17 (Visit 9; approximately 17 weeks after first dose).

Secondary outcomes

  1. Toxicity Measured by NCI CTCAE v5.0 (National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0)

    Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. A treatment-emergent adverse event (TEAE) was defined as any adverse event arising or worsening after the first dose of study drug. The number of participants experiencing at least one TEAE was summarized in the Safety Evaluation Set.

    Time frame: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).

Other outcomes

  1. Treatment Duration (Days)

    The number of days between the first and last doses of study treatment. Subjects who discontinued early have duration calculated to their final dose date.

    Time frame: From Treatment Start (Cycle 1 Day 1) to End of Treatment (EOT). Duration varies by subject.

  2. Treatment Compliance

    Percentage of study-drug doses received relative to the number of doses planned per protocol. Computed as: Compliance (%) = (Actual doses received ÷ Planned doses) × 100. Missed or undocumented doses are counted as not received unless justified per protocol or Statistical Analysis Plan (SAP). Dose holds and reductions are included in compliance assessment.

    Time frame: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).

  3. Cumulative Dose (mg)

    Total amount of imetelstat (mg) received across all treatment administrations. Calculated as the sum of all administered doses documented in the dose-administration eCRF (electronic Case Report Form). Notes: Dose reductions, missed doses, and dose delays are captured in the calculation. Missing dose records default to "not administered" unless clarified.

    Time frame: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject)

07

Results

Posted May 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneImetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)
Started2323
Completed03
Not completed2320
Withdrew: Death1513
Withdrew: Adverse event22
Withdrew: Physician decision40
Withdrew: Withdrawal by subject01
Withdrew: Progressive disease12
Withdrew: Treatment inefficiency01
Withdrew: Per protocol decision10
Withdrew: Ongoing in the extension phase at data cutoff01

Outcome measures

PrimaryOverall Hematological Response Rate of Participants After Treatment With Imetelstat

The combined response assessment criteria for MDS and AML based on IWG (International Working Group) 2018 criteria (MDS) and the criteria of the European LeukemiaNet (AML) will be used to define responders. The response rate is calculated as number of responders divided by the number of all participants of the analysis set.

Time frame:
Up to Week 17 (Visit 9; approximately 17 weeks after first dose).
Reported as:
Count of participants · Participants
Overall Hematological Response Rate of Participants After Treatment With Imetelstat
ParticipantsImetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)
Overall Hematological Response Rate of Participants After Treatment With Imetelstat01
SecondaryToxicity Measured by NCI CTCAE v5.0 (National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0)

Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. A treatment-emergent adverse event (TEAE) was defined as any adverse event arising or worsening after the first dose of study drug. The number of participants experiencing at least one TEAE was summarized in the Safety Evaluation Set.

Time frame:
From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).
Reported as:
Number · participants
Toxicity Measured by NCI CTCAE v5.0 (National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0)
participantsImetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)
Toxicity Measured by NCI CTCAE v5.0 (National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0)2323
Other pre-specifiedTreatment Duration (Days)

The number of days between the first and last doses of study treatment. Subjects who discontinued early have duration calculated to their final dose date.

Time frame:
From Treatment Start (Cycle 1 Day 1) to End of Treatment (EOT). Duration varies by subject.
Reported as:
Mean · days
Treatment Duration (Days)
daysImetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)
Treatment Duration (Days)53.8 ± 27.676.8 ± 71.7
Other pre-specifiedTreatment Compliance

Percentage of study-drug doses received relative to the number of doses planned per protocol. Computed as: Compliance (%) = (Actual doses received ÷ Planned doses) × 100. Missed or undocumented doses are counted as not received unless justified per protocol or Statistical Analysis Plan (SAP). Dose holds and reductions are included in compliance assessment.

Time frame:
From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).
Reported as:
Mean · percentage
Treatment Compliance
percentageImetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)
Treatment Compliance70 ± 2060 ± 30
Other pre-specifiedCumulative Dose (mg)

Total amount of imetelstat (mg) received across all treatment administrations. Calculated as the sum of all administered doses documented in the dose-administration eCRF (electronic Case Report Form). Notes: Dose reductions, missed doses, and dose delays are captured in the calculation. Missing dose records default to "not administered" unless clarified.

Time frame:
From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject)
Reported as:
Mean · Milligrams
Cumulative Dose (mg)
MilligramsImetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)
Cumulative Dose (mg)1502.32 ± 511.082564.65 ± 1290.84

Adverse events

Collected over Adverse events were collected from informed consent until 28 (±5) days, up tp 1 month, after the last dose. Serious Adverse Events (SAEs) suspected to be related to imetelstat were collected at any time after discontinuation and documented without time limit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imetelstat Sodium (1 Treatment / Cycle)15/23 (65.2%)18/23 (78.3%)23/23 (100%)
Imetelstat Sodium (2 Treatments / Cycle)13/23 (56.5%)19/23 (82.6%)23/23 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventImetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)
Transformation to acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/232/23
Febrile neutropeniaBlood and lymphatic system disorders3/234/23
Disease progressionGeneral disorders3/232/23
PneumoniaInfections and infestations3/230/23
PyrexiaGeneral disorders0/232/23
SepsisInfections and infestations1/232/23
AnaemiaBlood and lymphatic system disorders0/231/23
ThrombocytopeniaBlood and lymphatic system disorders0/231/23
Cardiac arrestCardiac disorders0/231/23
Cardio-respiratory arrestCardiac disorders0/231/23
Most frequent other events
Showing 10 of 164
Most frequent other events
EventImetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)
AstheniaGeneral disorders8/237/23
DiarrhoeaGastrointestinal disorders5/236/23
Coronavirus infectionInfections and infestations6/231/23
ConstipationGastrointestinal disorders2/235/23
NauseaGastrointestinal disorders1/235/23
Oedema peripheralGeneral disorders2/235/23
AnxietyPsychiatric disorders5/232/23
LeukocytosisBlood and lymphatic system disorders4/233/23
NeutropeniaBlood and lymphatic system disorders4/232/23
ThrombocytopeniaBlood and lymphatic system disorders2/234/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)Imetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)Total
Mean77.5 ± 4.877.7 ± 6.277.6 ± 5.5
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Imetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)Total
Male151429
Female8917
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Imetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White9615
More than one race000
Unknown or Not Reported141630
WHO (World Health Organization) 2016 Disease Classification (MDS vs AML)
WHO (World Health Organization) 2016 Disease Classification (MDS vs AML)(Participants)Imetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)Total
MDS (Myelodysplastic Syndromes)6511
AML (Acute Myeloid Leukemia)171835
IPSS-R Risk Category
IPSS-R Risk Category(Participants)Imetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)Total
Intermediate Risk022
High Risk101
Very High Risk448
Score not done for AML181735
Cytogenetic Risk (Karyotype)
Cytogenetic Risk (Karyotype)(Participants)Imetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)Total
Good123
Intermediate112
Poor314
Very poor022
Score not done for AML181735
Prior Azacitidine (AZA) cycles
Prior Azacitidine (AZA) cycles(Participants)Imetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)Total
1-6 cycles7512
7-12 cycles8816
13-24 cycles3710
≥25 cycles5611
Prior Venetoclax (VEN) cycles
Prior Venetoclax (VEN) cycles(participants)Imetelstat Sodium (1 Treatment / Cycle)Imetelstat Sodium (2 Treatments / Cycle)Total
1-6 cycles8513
7-12 cycles325
13-24 cycles112
≥25 cycles112

4 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • Royal Adelaide Hospital
    Adelaide, Australia
  • Royal Brisbane and Women's Hospitals
    Brisbane, Australia
  • Linear Clinical Research
    Nedlands, Australia
  • CHU Nantes - Hôtel Dieu
    Nantes, France
  • Hôpital Archet 1
    Nice, France
  • Hôpital Saint-Louis
    Paris, France
  • CHU de Toulouse
    Toulouse, France
  • Marien Hospital Düsseldorf
    Düsseldorf, Germany
  • Universität Jena, Medizinische Fakultät
    Jena, Germany
  • Universität Leipzig, Medizinische Fakultät
    Leipzig, Germany
  • Klinikum rechts der Isar
    München, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Mar 2025, 21 months.

Results were first posted in May 2026, 1 year 1 month after primary completion.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 21 months is below that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2025, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2022
First posted
Oct 17, 2022
StartActual
Jun 5, 2023
Primary completionActual
Mar 27, 2025
CompletionActual
Sep 30, 2025was Jun 2026
Results first posted
May 12, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 2, 2026
Study completion
Jun 2026→Sep 30, 2025 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Active, not recruiting→Completed
    Study completion Jun 2026→Sep 30, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05583552
Lead sponsor
GCP-Service International West GmbH
Collaborators
Geron Corporation, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, QIMR Berghofer Medical Research Institute, Australasian Leukaemia and Lymphoma Group, Groupe Francophone des Myelodysplasies, German Myelodysplastic Syndrome Study Group
Responsible party
Sponsor
First posted
Oct 17, 2022
Start date
Jun 5, 2023
Primary completion
Mar 27, 2025
Completion
Sep 30, 2025
Results posted
May 12, 2026
Last update
Oct 2, 2026

Study contacts

Uwe Platzbecker, MD
principal investigator · Universitätsklinikum Leipzig

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imetelstat

Start the discussion